- Home
- VLO vs SNY Comparison
VLO vs SNY Comparison
Compare VLO & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VLO | SNY |
|---|---|---|
| Founded | 1980 | 1994 |
| Country | United States | France |
| Employees | 9811 | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.5B | 104.5B |
| IPO Year | 1997 | 2001 |
Fundamental Metrics
Financial Performance| Metric | VLO | SNY |
|---|---|---|
| Price | $386.21 | $41.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 5 |
| Target Price | ★ $232.17 | $58.00 |
| AVG Volume (30 Days) | ★ 3.3M | 2.2M |
| Earning Date | 04-30-2026 | 04-23-2026 |
| Dividend Yield | 1.91% | ★ 3.47% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 16.78 | N/A |
| Revenue | ★ $122,687,000,000.00 | N/A |
| Revenue This Year | $9.62 | $3.49 |
| Revenue Next Year | N/A | $6.10 |
| P/E Ratio | $22.82 | ★ $6.14 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $155.29 | $40.89 |
| 52 Week High | $419.04 | $52.68 |
Technical Indicators
Market Signals| Indicator | VLO | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 58.22 | 31.03 |
| Support Level | $226.98 | N/A |
| Resistance Level | N/A | $45.22 |
| Average True Range (ATR) | 17.18 | 0.51 |
| MACD | -3.51 | -0.23 |
| Stochastic Oscillator | 40.29 | 12.97 |
Price Performance
Historical ComparisonAbout VLO Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 15 refineries, with a total throughput capacity of 3.2 million barrels a day in the US, Canada, and the United Kingdom. Valero also owns 12 ethanol plants with capacity of 1.6 billion gallons a year and holds a 50% stake in Diamond Green Diesel, which can produce 1.2 billion gallons per year of renewable diesel.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.